Tipologia

Indietro Universal Hepatitis B Vaccination in Adults Aged 19–59 Years: Updated Recommendations of the Advisory Committee on Immunization Practices — United States, 2022 | MMWR

What is already known about this topic?

Vaccination with hepatitis B (HepB) vaccines shows well-established safety and efficacy. However, because of risk factor−based approaches of previous vaccination recommendations, coverage among adults has been suboptimal.

What is added by this report?

In addition to groups for whom HepB vaccination is already recommended, the Advisory Committee on Immunization Practices recommends that all adults aged 19–59 years should receive HepB vaccines.

What are the implications for public health practice?

Universal adult HepB vaccination through age 59 years removes the need for risk factor screening and disclosure and could increase vaccination coverage and decrease hepatitis B cases.

Entire content available on: https://www.cdc.gov/mmwr/volumes/71/wr/mm7113a1.htm?s_cid=mm7113a1_x



Lingua

Inglese

Tipologia

Articoli scientifici/Reviews

Argomento

Vaccini Malattie infettive

Profilo

Salute pubblica

Paese

USA